Jena Discusses New PHE Preeclampsia Study with Orlando Sentinel
PHE Scientific Advisor Anupam Jena, coauthor of a new study on preeclampsia in the September issue of American Journal of Obstetrics & Gynecology, discussed the study’s findings and the growing economic impact of the condition with the Orlando Sentinel’s Amelia Cheatham.
The study by Jena and colleagues found that preeclampsia increases the probability of an adverse event for mothers and infants and lowers the gestational age. The authors estimated preeclampsia cost the US healthcare system an additional $2.18 billion above the usual maternal and infant costs in 2012. PHE’s study sheds light on an important health factor during pregnancy. “We don’t really know much about how preeclampsia impacts both the short-term and long-term health of mothers and their infants on a national scale,” Jena said.
To read the article in the Orlando Sentinel, please click here.
To read the study abstract as it appears in the American Journal of Obstetrics & Gynecology, please click here.
By: Jason Shafrin, PhD Sr. Director, Policy and Economics and Jacki Chou, MPL Senior Director, Policy and Economics The recent announcement that CVS Caremark will use value-based metrics to inform formulary design at first appears a step in the right direction. However, using value measurements from a single nongovernmental organization—the Institute for Clinical and Economic Review (ICER)—based on a limited picture of treatment value may be problematic. Using this single assessment of value in an effort solely to exclude drugs from a major insurance formulary is even more worrisome and fails to recognize the heterogeneity in patient clinical needs and preferences.